An experimental drug, once hoped to be the next significant advance in preventing heart attacks and strokes, has failed a crucial test, researchers announced. The medicine, designed to lower levels of a blood particle linked to heart attacks and strokes, did not protect study participants. Steven Nissen, a cardiologist at the Cleveland Clinic who led the study, expressed his surprise and disappointment at the outcome.
Cardiovascular disease remains the leading cause of death in developed countries. This research aimed to aid individuals who maintain healthy lifestyles—those who control cholesterol and blood pressure, eat well, exercise, and keep a healthy weight—yet still suffer heart attacks and strokes. Many such patients have elevated levels of lipoprotein(a) or Lp(a), a cholesterol-carrying protein thought to increase heart disease risk.
Researchers have long sought a drug to lower Lp(a) levels. Until recently, no medications were available for this. However, several experimental drugs have emerged, designed to significantly reduce elevated Lp(a). Nissen’s team conducted a study with 8,350 adults already diagnosed with heart disease. Participants received either a placebo or the drug pelacarsen, which reduces Lp(a) by 78%.
Despite this reduction, the five-year study did not show a decrease in cardiovascular complications. Nissen described the results as disappointing during a presentation at an American Heart Association meeting in Chicago. Details were published in the New England Journal of Medicine and NEJM Evidence.
Novartis, the drugmaker behind the study, acknowledged the results did not meet expectations yet claimed the study provided meaningful insights into Lp(a) and heart disease. According to the company, such studies are essential for advancing scientific understanding, even when outcomes are not as anticipated.
What went wrong?
The study’s failure has puzzled many in the scientific community who believed Lp(a)-lowering drugs would become a crucial tool in combating cardiovascular disease, responsible for over 900,000 deaths in the U.S. annually. Harlan Krumholz, a cardiologist at Yale University, noted the unexpected nature of the result.
Researchers are considering various explanations. High Lp(a) might not directly cause heart attacks and strokes but serve as a marker indicating another risk factor. Some experts, including Roger Blumenthal from Johns Hopkins University, suggest longer or earlier treatment might be necessary, whereas others, like David Maron from Stanford University, propose the study should have targeted individuals with higher Lp(a) levels.
The trial’s outcome might also be drug-specific. Other experimental medications might yield different results. Companies like Amgen and Eli Lilly are testing their Lp(a)-lowering drugs, with findings expected in the upcoming years.
Karol Watson, a cardiologist from the University of California, Los Angeles, emphasized the ongoing nature of the research. Although this particular attempt did not succeed, the quest to find effective treatments for cardiovascular diseases continues.
